Quantification of Age and Sex Ratio Differences between Trial and Target Population for New Drugs
Open Access
- 1 February 2026
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 119 (4) , 1105-1111
Abstract
Clinical trials are essential to understand the benefit‐harm profile of new drugs. Lack of adequate representation in age and sex ratio in clinical trials can result, for example, in higher side effects for underrepresented patients. We quantified differences in age and sex ratios between trial and target populations of new drugs approved by the FDA 2011–2022. We used the FDA's database to identify all new drugs and pivotal randomized trials. Information for average age and sex ratio was obtained from clinicaltrials.gov . Each trial's indication was matched with prevalence estimates of the targeted diseases from the global burden of disease study. A total of 458 drugs (773 trials) were included. The trial populations were significantly younger, on average 4.8 years (95% CI [5.4 years, 4.2 years]), and the female ratio significantly smaller, on average 4.3 percentage points (95% CI [5.4 pp, 3.3 pp]), than the target populations. For diseases with average patient age below 40, the trial population was significantly older than the target population but significantly younger 40 years and older. For diseases with average age between 30 and 39, the female ratio in the trial population was significantly higher than in the target population but significantly lower 50 and older. Better age and sex ratio representation in the trial population is indicated to improve safety and efficacy for patients. Trials targeting diseases below 40 should enroll younger participants and increase their male ratio, while the opposite is true for trials targeting diseases with an older age.Keywords
This publication has 31 references indexed in Scilit:
- The Integration of Clinical Trials With the Practice of MedicineJAMA, 2024
- Exclusion of Women from Phase I Trials: Perspectives from Investigators and Research Oversight OfficialsEthics & Human Research, 2023
- Male involvement in randomised trials testing psychotherapy or behavioural interventions for depression: a scoping reviewCurrent Psychology, 2022
- Participation of Older Adults in Clinical Trials for New Drug Applications and Biologics License Applications From 2010 Through 2019JAMA Network Open, 2022
- Depression's Problem With MenAMA Journal of Ethics, 2021
- Feasibility of Using Real-World Data to Replicate Clinical Trial EvidenceJAMA Network Open, 2019
- Quantifying Sex Bias in Clinical Studies at Scale With Automated Data ExtractionJAMA Network Open, 2019
- The Experience of Symptoms of Depression in Men vs WomenJAMA Psychiatry, 2013
- Women encounter ADRs more often than do menEuropean Journal of Clinical Pharmacology, 2008
- Gender differences in depressionEuropean Archives of Psychiatry and Clinical Neuroscience, 2002